JP2015524444A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015524444A5 JP2015524444A5 JP2015525640A JP2015525640A JP2015524444A5 JP 2015524444 A5 JP2015524444 A5 JP 2015524444A5 JP 2015525640 A JP2015525640 A JP 2015525640A JP 2015525640 A JP2015525640 A JP 2015525640A JP 2015524444 A5 JP2015524444 A5 JP 2015524444A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- pharmaceutical composition
- 2hpβcd
- composition according
- additional therapeutic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261679668P | 2012-08-03 | 2012-08-03 | |
| US61/679,668 | 2012-08-03 | ||
| PCT/US2013/053527 WO2014022841A1 (en) | 2012-08-03 | 2013-08-03 | Cyclodextrin for the treatment of lysosomal storage diseases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018116666A Division JP2018162277A (ja) | 2012-08-03 | 2018-06-20 | ライソゾーム蓄積症を治療するためのシクロデキストリン |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015524444A JP2015524444A (ja) | 2015-08-24 |
| JP2015524444A5 true JP2015524444A5 (enExample) | 2016-09-23 |
Family
ID=49170855
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015525640A Pending JP2015524444A (ja) | 2012-08-03 | 2013-08-03 | ライソゾーム蓄積症を治療するためのシクロデキストリン |
| JP2018116666A Pending JP2018162277A (ja) | 2012-08-03 | 2018-06-20 | ライソゾーム蓄積症を治療するためのシクロデキストリン |
| JP2020026808A Active JP6858286B2 (ja) | 2012-08-03 | 2020-02-20 | ライソゾーム蓄積症を治療するためのシクロデキストリン |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018116666A Pending JP2018162277A (ja) | 2012-08-03 | 2018-06-20 | ライソゾーム蓄積症を治療するためのシクロデキストリン |
| JP2020026808A Active JP6858286B2 (ja) | 2012-08-03 | 2020-02-20 | ライソゾーム蓄積症を治療するためのシクロデキストリン |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20150216895A1 (enExample) |
| EP (1) | EP2879714B1 (enExample) |
| JP (3) | JP2015524444A (enExample) |
| CN (2) | CN107865968B (enExample) |
| AU (2) | AU2013296170A1 (enExample) |
| CA (1) | CA2880880C (enExample) |
| WO (1) | WO2014022841A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2880880C (en) | 2012-08-03 | 2021-01-26 | John Mckew | Cyclodextrin for the treatment of lysosomal storage diseases |
| WO2015083736A1 (ja) | 2013-12-05 | 2015-06-11 | 国立大学法人熊本大学 | コレステロール蓄積疾患治療薬、およびそのスクリーニング方法 |
| KR20170012555A (ko) | 2014-06-12 | 2017-02-02 | 더 유니버시티 오브 노트르 담 듀락 | 신경 질환 및 대뇌 상해의 치료를 위한 조성물 및 방법 |
| US10239830B2 (en) * | 2015-02-11 | 2019-03-26 | Icahn School Of Medicine At Mount Sinai | Benzenesulfonamide upregulators of NPC1 for Neimann-Pick disease and other lysosomal storage disorders |
| AU2016276774A1 (en) | 2015-06-10 | 2018-01-18 | Vtesse, Inc. | Hydroxypropyl beta-cyclodextrin compositions and methods |
| EP3405501B1 (en) * | 2016-01-21 | 2023-11-15 | Aten Porus Lifesciences | Cyclodextrin based polymers, methods, compositions and applications thereof |
| IL298681A (en) | 2016-08-02 | 2023-01-01 | Univ Virginia Commonwealth | Preparations |
| CN109982718A (zh) | 2016-09-19 | 2019-07-05 | 阿托恩波罗斯生命科学 | 基于环糊精的聚合物、方法、组合物及其应用 |
| JPWO2018199287A1 (ja) * | 2017-04-28 | 2020-03-12 | 国立大学法人京都大学 | クリスタリン網膜症の処置および／または予防方法 |
| WO2019067145A1 (en) * | 2017-08-28 | 2019-04-04 | Asdera Llc | USE OF CYCLODEXTRINS IN DISEASES AND DISORDERS INVOLVING PHOSPHOLIPID DISRUPTION |
| JP2020535235A (ja) * | 2017-09-28 | 2020-12-03 | アスデラ エルエルシー | リン脂質の調節異常が関与する疾患および障害におけるシクロデキストリンの使用 |
| EP3873604B1 (en) | 2018-10-29 | 2024-08-21 | Cyclo Therapeutics, Inc. | Methods for treating alzheimer's disease with hp-[beta]-cyclodextrin |
| AU2020204925B2 (en) | 2019-01-03 | 2025-11-20 | Cyclarity Therapeutics, Inc. | Cyclodextrin dimers, compositions thereof, and uses thereof |
| JP7264452B2 (ja) * | 2019-04-15 | 2023-04-25 | 塩水港精糖株式会社 | ライソゾーム病の治療または予防のための医薬組成物 |
| US12226431B2 (en) | 2021-09-11 | 2025-02-18 | Porosome Therapeutics, Inc. | Aerosol and topical administration of a formulation containing cyclodextrin, quercetin and zinc, in combination or separately, to mitigate infection by enveloped viruses |
| JP7551339B2 (ja) * | 2020-06-04 | 2024-09-17 | 株式会社三共 | 遊技機 |
| JP7551340B2 (ja) * | 2020-06-04 | 2024-09-17 | 株式会社三共 | 遊技機 |
| WO2022051631A1 (en) * | 2020-09-03 | 2022-03-10 | University Of Notre Dame Du Lac | Therapy to stimulate hippocampal neural progenitors and adult neurogenesis |
| US11446325B2 (en) * | 2020-09-30 | 2022-09-20 | Cyclolab Cyclodextrin Research And Development Laboratory Ltd. | Cyclodextrin derivatives in the treatment or prevention of lysosomal neurodegenerative diseases |
| JP2025506676A (ja) | 2022-02-18 | 2025-03-13 | ベレン セラピューティクス ピー．ビー．シー． | ヒドロキシプロピル－ベータ－シクロデキストリンの組成物及びその精製方法 |
| WO2025090588A1 (en) | 2023-10-24 | 2025-05-01 | Minerva Neurosciences, Inc. | Roluperidone for the treatment of lysosomal storage disorders and their symptoms |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4727064A (en) | 1984-04-25 | 1988-02-23 | The United States Of America As Represented By The Department Of Health And Human Services | Pharmaceutical preparations containing cyclodextrin derivatives |
| US6407079B1 (en) | 1985-07-03 | 2002-06-18 | Janssen Pharmaceutica N.V. | Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| US5262404A (en) | 1990-02-15 | 1993-11-16 | The Trustees Of The University Of Pennsylvania/Childrens Hospital Corporation | Cyclodextrin polymers and cyclodextrins immobilized on a solid surface |
| EP0803243B1 (en) | 1996-04-24 | 2003-03-19 | Pfizer Inc. | Cyclodextrins and phenolic compounds in dental products |
| FR2767834B1 (fr) | 1997-08-29 | 1999-12-03 | Inst Francais Du Petrole | Mono et di-derives de cyclodextrines, leurs synthese et purification et leur utilisation en support |
| AU2001259725A1 (en) | 2000-05-15 | 2001-11-26 | The Procter And Gamble Company | Compositions comprising cyclodextrin derivatives |
| US7442372B2 (en) * | 2003-08-29 | 2008-10-28 | Biomarin Pharmaceutical Inc. | Delivery of therapeutic compounds to the brain and other tissues |
| WO2005112637A1 (en) * | 2004-05-14 | 2005-12-01 | Decode Chemistry, Inc. | Formulations for non-parenteral use including hydrophobic cyclodextrins |
| EP1655034A1 (en) | 2004-10-10 | 2006-05-10 | Université de Liège | Use of cyclodextrin for treatment and prevention of bronchial inflammatory diseases. |
| US20090258001A1 (en) * | 2006-06-06 | 2009-10-15 | Paul Ponath | Administration of anti-CD3 antibodies in the treatment of autoimmune diseases |
| US20120077774A1 (en) * | 2009-05-28 | 2012-03-29 | Cornell University | Compositions and their use for removing cholesterol |
| US9044451B2 (en) * | 2010-07-19 | 2015-06-02 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Use of delta tocopherol for the treatment of lysosomal storage disorders |
| WO2012100142A2 (en) * | 2011-01-20 | 2012-07-26 | Cornell University | Treatments for retinal disorders |
| CA2880880C (en) | 2012-08-03 | 2021-01-26 | John Mckew | Cyclodextrin for the treatment of lysosomal storage diseases |
| FR3014694B1 (fr) | 2013-12-13 | 2016-11-11 | Roquette Freres | Compositions a base de methyl-cyclodextrines pour le traitement et/ou la prevention de maladies par augmentation du taux de cholesterol-hdl |
-
2013
- 2013-08-03 CA CA2880880A patent/CA2880880C/en active Active
- 2013-08-03 US US14/419,471 patent/US20150216895A1/en not_active Abandoned
- 2013-08-03 EP EP13762617.2A patent/EP2879714B1/en active Active
- 2013-08-03 CN CN201711057517.4A patent/CN107865968B/zh active Active
- 2013-08-03 AU AU2013296170A patent/AU2013296170A1/en not_active Abandoned
- 2013-08-03 WO PCT/US2013/053527 patent/WO2014022841A1/en not_active Ceased
- 2013-08-03 JP JP2015525640A patent/JP2015524444A/ja active Pending
- 2013-08-03 CN CN201380052023.0A patent/CN104684585A/zh active Pending
-
2017
- 2017-06-12 US US15/620,753 patent/US11020422B2/en active Active
-
2018
- 2018-04-30 AU AU2018202964A patent/AU2018202964B2/en active Active
- 2018-06-20 JP JP2018116666A patent/JP2018162277A/ja active Pending
-
2020
- 2020-02-20 JP JP2020026808A patent/JP6858286B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015532296A5 (enExample) | ||
| EA201270221A1 (ru) | Лечение болезни крона с применением лаквинимода | |
| JP2017506624A5 (enExample) | ||
| NZ586751A (en) | Use of CDDO methyl ester (methyl 2-cyano-3,12-dioxoleana-1,9(11)-dien-28-oate) for the treatment of renal diseases and for improving kigney function | |
| JP2012526855A5 (enExample) | ||
| JP2014516942A5 (enExample) | ||
| JP2012255026A5 (enExample) | ||
| HRP20220902T3 (hr) | Pripravci i njihova upotreba u liječenju multiple skleroze | |
| JP2009500443A5 (enExample) | ||
| NZ590291A (en) | Pharmaceutical compositions for treatment of parkinson's disease | |
| JP2012520866A5 (enExample) | ||
| UA107578C2 (uk) | Комбінована терапія при лікуванні діабету | |
| HRP20150644T1 (hr) | Metoda za lijeäśenje atrijalne fibrilacije | |
| NZ605469A (en) | Nalbuphine-based formulations and uses thereof | |
| HK1206246A1 (en) | Use of high dose laquinimod for treating multiple sclerosis | |
| NZ593467A (en) | Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof | |
| MX2012000275A (es) | Antagonista de bomba de acido para el tratamiento de enfermedades involucradas en la motilidad gastrointestinal anormal. | |
| JP2013509411A5 (enExample) | ||
| MX2009003372A (es) | Formas de dosificacion de pelicula no mucoadhesiva. | |
| JP2013541583A5 (enExample) | ||
| WO2011151722A3 (en) | Methods and compositions for oral pharmaceutical therapy | |
| EA200700214A1 (ru) | Мемантин в качестве дополнительной терапии к атипичным антипсихотическим средствам у больных шизофренией | |
| JP2021502392A5 (enExample) | ||
| WO2017182873A3 (en) | Peptide-oligourea foldamer compounds and methods of their use | |
| JP2014512355A5 (enExample) |